Advertisement

Rheumatology International

, Volume 39, Issue 4, pp 689–695 | Cite as

MicroRNA-124 inhibits TNF-α- and IL-6-induced osteoclastogenesis

  • Kenichiro Ohnuma
  • Shimpei Kasagi
  • Kenichi Uto
  • Yoriko Noguchi
  • Yuji Nakamachi
  • Jun Saegusa
  • Seiji KawanoEmail author
Bone and Cartilage

Abstract

Receptor activator for nuclear factor κB ligand (RANKL)-independent osteoclastogenic pathway was reported recently. MicroRNA (miR)-124 has been known to suppress RANKL-dependent osteoclastogenesis by inhibiting NFATc1 expression. However, whether miR-124 regulates a RANKL-independent pathway has not been elucidated. In this study, we examined whether a RANKL-independent pathway is regulated by miR-124 in addition to the RANKL-dependent one. Using osteoclastogenic culture and pit-formation assay, we found that a miR-124 mimic inhibited osteoclastogenesis in mouse bone marrow-derived macrophages stimulated by TNF-α, IL-6, and M-CSF in the presence of osteoprotegerin. We also showed that the expression levels of osteoclast-specific genes and NFATc1 protein were suppressed in the miR-124 mimic-transfected cells by performing quantitative-polymerase chain reaction and western blotting. Our results indicate that miR-124 is important in inhibiting both RANKL-dependent and -independent osteoclast differentiation by suppressing NFATc1-mediated pathway.

Keywords

MicroRNA-124 Rheumatoid arthritis Osteoclast Tumor necrosis factor-α Interleukin-6 RANKL-independent osteoclastogenesis 

Notes

Acknowledgements

We would like to thank Clarity Editing for English proofreading.

Author contributions

Conceptualization: SK. Data curation and making figures and graphs: KO. Formal analysis: SK, JS. Investigation: YN, YN, KU. Methodology: SK, JS, SK. Integration of the study: KO, SK, JS, SK. Supervision: SK. Writing ± original draft: KO. Writing ± review and editing: SK, JS, SK.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest. This study was approved by the Institutional Animal Care and Use Committee of Kobe University.

Supplementary material

296_2018_4218_MOESM1_ESM.pptx (40 kb)
Supplementary material 1 (PPTX 41 KB)
296_2018_4218_MOESM2_ESM.pptx (39 kb)
Supplementary material 2 (PPTX 39 KB)

References

  1. 1.
    McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219.  https://doi.org/10.1056/NEJMra1004965 CrossRefGoogle Scholar
  2. 2.
    Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038.  https://doi.org/10.1016/s0140-6736(16)30173-8 CrossRefGoogle Scholar
  3. 3.
    Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337–342.  https://doi.org/10.1038/nature01658 CrossRefGoogle Scholar
  4. 4.
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95(7):3597–3602CrossRefGoogle Scholar
  5. 5.
    Hattersley G, Owens J, Flanagan AM, Chambers TJ (1991) Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitro. Biochem Biophys Res Commun 177(1):526–531CrossRefGoogle Scholar
  6. 6.
    Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3(6):889–901CrossRefGoogle Scholar
  7. 7.
    Hemingway F, Taylor R, Knowles HJ, Athanasou NA (2011) RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 48(4):938–944.  https://doi.org/10.1016/j.bone.2010.12.023 CrossRefGoogle Scholar
  8. 8.
    Yokota K, Sato K, Miyazaki T, Kitaura H, Kayama H, Miyoshi F, Araki Y, Akiyama Y, Takeda K, Mimura T (2014) Combination of tumor necrosis factor alpha and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol 66(1):121–129.  https://doi.org/10.1002/art.38218 CrossRefGoogle Scholar
  9. 9.
    O’Brien W, Fissel BM, Maeda Y, Yan J, Ge X, Gravallese EM, Aliprantis AO, Charles JF (2016) RANK-independent osteoclast formation and bone erosion in inflammatory arthritis. Arthritis Rheumatol 68(12):2889–2900.  https://doi.org/10.1002/art.39837 CrossRefGoogle Scholar
  10. 10.
    Nakamachi Y, Kawano S, Takenokuchi M, Nishimura K, Sakai Y, Chin T, Saura R, Kurosaka M, Kumagai S (2009) MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 60(5):1294–1304.  https://doi.org/10.1002/art.24475 CrossRefGoogle Scholar
  11. 11.
    Nakamachi Y, Ohnuma K, Uto K, Noguchi Y, Saegusa J, Kawano S (2016) MicroRNA-124 inhibits the progression of adjuvant-induced arthritis in rats. Ann Rheum Dis 75(3):601–608.  https://doi.org/10.1136/annrheumdis-2014-206417 CrossRefGoogle Scholar
  12. 12.
    Lee Y, Kim HJ, Park CK, Kim YG, Lee HJ, Kim JY, Kim HH (2013) MicroRNA-124 regulates osteoclast differentiation. Bone 56(2):383–389.  https://doi.org/10.1016/j.bone.2013.07.007 CrossRefGoogle Scholar
  13. 13.
    Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381(9877):1541–1550.  https://doi.org/10.1016/s0140-6736(13)60250-0 CrossRefGoogle Scholar
  14. 14.
    van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzova D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA, Investigators OS (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65(3):559–570.  https://doi.org/10.1002/art.37816 CrossRefGoogle Scholar
  15. 15.
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594–1602.  https://doi.org/10.1056/nejm200011303432202 CrossRefGoogle Scholar
  16. 16.
    Tang P, Xiong Q, Ge W, Zhang L (2014) The role of microRNAs in osteoclasts and osteoporosis. RNA Biol 11(11):1355–1363.  https://doi.org/10.1080/15476286.2014.996462 CrossRefGoogle Scholar
  17. 17.
    Shibuya H, Nakasa T, Adachi N, Nagata Y, Ishikawa M, Deie M, Suzuki O, Ochi M (2013) Overexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation. Mod Rheumatol 23(4):674–685.  https://doi.org/10.1007/s10165-012-0710-1 CrossRefGoogle Scholar
  18. 18.
    Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M (2011) The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 63(6):1582–1590.  https://doi.org/10.1002/art.30321 CrossRefGoogle Scholar
  19. 19.
    Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T (2010) Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 12(3):R86.  https://doi.org/10.1186/ar3013 CrossRefGoogle Scholar
  20. 20.
    Park JS, Jeong JH, Byun JK, Lim MA, Kim EK, Kim SM, Choi SY, Park SH, Min JK, Cho ML (2017) Regulator of calcineurin 3 ameliorates autoimmune arthritis by suppressing Th17 cell differentiation. Am J Pathol 187(9):2034–2045.  https://doi.org/10.1016/j.ajpath.2017.05.008 CrossRefGoogle Scholar
  21. 21.
    Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368(18):1685–1694.  https://doi.org/10.1056/NEJMoa1209026 CrossRefGoogle Scholar
  22. 22.
    Montgomery RL, Yu G, Latimer PA, Stack C, Robinson K, Dalby CM, Kaminski N, van Rooij E (2014) MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med 6(10):1347–1356.  https://doi.org/10.15252/emmm.201303604 CrossRefGoogle Scholar
  23. 23.
    Liu J, Dang L, Li D, Liang C, He X, Wu H, Qian A, Yang Z, Au DW, Chiang MW, Zhang BT, Han Q, Yue KK, Zhang H, Lv C, Pan X, Xu J, Bian Z, Shang P, Tan W, Liang Z, Guo B, Lu A, Zhang G (2015) A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. Biomaterials 52:148–160.  https://doi.org/10.1016/j.biomaterials.2015.02.007 CrossRefGoogle Scholar
  24. 24.
    Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y (2013) Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24(4):542–556.  https://doi.org/10.1016/j.ccr.2013.09.008 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Kenichiro Ohnuma
    • 1
    • 2
  • Shimpei Kasagi
    • 1
    • 2
  • Kenichi Uto
    • 2
  • Yoriko Noguchi
    • 2
  • Yuji Nakamachi
    • 2
  • Jun Saegusa
    • 1
    • 2
  • Seiji Kawano
    • 1
    Email author
  1. 1.Division of Laboratory MedicineKobe University Graduate School of MedicineKobeJapan
  2. 2.Department of Clinical LaboratoryKobe University HospitalKobeJapan

Personalised recommendations